Interestingly, a recent study showed that metastatic prostate cancers are heterogeneous for that concerns AR/AR signaling expression and neuroendocrine features and, according to these two parameters, can be subdivided into three subgroups: AR+/NE-, AR-/NE+, and AR-/NE- [215]. The gene discussed is AR; the disease is prostate carcinoma.